

Clinical trials of VEGF gene

TrialResults-center www.trialresultscenter.org

1 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
VEGF gene transfer vs control			
REVASC (Stewart) , 2006 n=NA follow-up:	AdVEGF121 gene transfer with epicardial injection at minithoracotomy versus control	patients with severe angina due to coronary artery disease and no conventional options for revascularization	open

More details and results :

- cell-based therapies for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q300>

References

REVASC (Stewart), 2006:

Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendelsohn FO, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler PD, Rasmussen HS Gene Ther 2006;13:1503-11 [[16791287](#)] [10.1038/sj.gt.3302802](https://doi.org/10.1038/sj.gt.3302802)

2 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
VEGF gene vs placebo			
Makinen , 2002 n=35/19 follow-up: 3 months	VEGF-adenovirus or VEGF plasmid versus placebo	patients with chronic lower-limb ischemia and atherosclerotic infrainguinal occlusion or stenosis undergoing percutaneous transluminal angioplasty	double blind

More details and results :

- cell-based therapies for peripheral vascular diseases in all type of patients at <http://www.trialresultscenter.org/go-Q335>

References

Makinen, 2002:

Mkinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E, Yl-Herttuala S Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. *Mol Ther* 2002;6:127-33 [[12095313](#)] [10.1006/mthe.2002.0638](#)